Legible Prescriptions a Fundamental Right: Punjab and Haryana HC directs doctors to use capital letters

Chandigarh: Observing that legible medical prescriptions and diagnosis form an essential part of a patient’s right to health under Article 21 of the Constitution, the Punjab and Haryana High Court directed doctors to write prescriptions and diagnosis notes in capital letters until computerisation or typed prescriptions become the norm. 

The directive follows a shocking incident where the court was unable to understand a single word from a medico-legal report concerning a rape case due to the illegible handwriting of the doctors involved. 

While considering the plea, the court noted that unclear or illegible handwriting in prescriptions can endanger patients’ lives and compromise their right to know what treatment is being given. It further noted that in the age of digital health and artificial intelligence, legible prescriptions are indispensable to ensure that the Fundamental Rights of the people of India are duly safeguarded.

Also read- Punjab Mandates 48-Hour Deadline for Submission of Medico-Legal Reports

Suggesting preventive measures, Single Bench Justice Jasgurpreet Singh Puri asked the National Medical Commission (NMC) to include the importance of clear and legible handwriting in medical prescriptions as part of the curriculum in all medical colleges. The Court said that digital or typed prescriptions should be made a priority across the country.

Holding that the right of patients to clearly understand their treatment is an integral part of the fundamental right to life under Article 21, the bench observed,

“This court is of the considered view that Right to Life and Personal Liberty guaranteed under Article 21 of the Constitution of India encompasses the Right to Health, which further includes the Right to Know one’s legible medical prescription, diagnosis, medical documents and treatment.”

As per a media report by Bar and Bench, the matter came up when the Court, while hearing a bail plea earlier this year, encountered an illegible medico-legal report. Taking suo motu cognizance, the bench sought responses from Punjab, Haryana, and the Union Territory of Chandigarh. Although the Indian Medical Association was asked to assist, it chose not to appear in the matter.

In subsequent hearings, the States informed the Court that doctors had already been directed to write prescriptions and diagnosis in capital or bold letters until computerised or typed prescriptions are fully implemented. 

In its final order, the Court directed that a comprehensive policy be framed to ensure complete computerisation of prescriptions within two years. It further emphasised that financial assistance must be provided to doctors and clinical establishments wherever required.

The Court remarked,

“While looking at the medico-legal report filed by the respondent-State along with reply as Annexure R-1, it shook the conscience of this Court as not even a word or a letter was legible. It is very surprising and shocking to note that in this era of technology and accessibility of computers, the notes on the medical history and prescriptions by Government doctors are still handwritten in a manner that cannot be read by anybody except perhaps some chemists.”

It further observed, “Everyone in today’s time is well informed and aware of as to how technology can be put to use in their day to day lives. In such progression of informed citizens, it becomes likely for most of us to check the medical prescription/diagnosis which has been provided by the doctor in order to lookout for any relevant information which might be available regarding the same on digital platforms. This practice has been further aided by the introduction of Artificial Intelligence, where all the curated information on any subject lies just a click away.”

The Court made it clear that this move is not about replacing doctors’ expertise with technology, but about ensuring patients’ safety and rights. It added that if prescriptions are unclear, it jeopardises the quality and safety of patients, hindering broader access to care and patients’ right to give free consent without having any knowledge as to what has been prescribed to them.

“The issue involved herein is not an issue of substitution, which otherwise could be counter productive to the health of patients, but the issue involved is only a right to know about the treatment being carried on towards him. Illegibility leads to ambiguity and confusion, which can in turn take on a patient’s life or health,” the Court said.

While acknowledging the hard work and dedication of doctors, the Court said,

“This Court holds the highest respect and regard for doctors and the medical profession, acknowledging their dedication to national service, but at the same time, it is equally important to ensure that the Fundamental Rights of the people of India are duly safeguarded.”

Also read- Right to Medical Reimbursement linked to Right to Life: HC

Powered by WPeMatico

100 Additional Delhi Hospitals to be added under Ayushman Bharat soon

Delhi Health Minister Dr Pankaj Singh on Thursday announced that the government will add 100 more hospitals under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) in the next 10 days. This move will increase the total number of empanelled hospitals in the capital to 165.

The updated list is expected to include prominent private hospitals such as Fortis Healthcare. A formal launch of the expanded network is scheduled for the first week of September.

According to the National Health Authority (NHA), which oversees the implementation of AB-PMJAY across India, 151 hospitals in Delhi are currently empanelled under the scheme—107 private and 44 government-run.

For more details, check out the full story on the link below:

Delhi Govt to empanel 100 additional hospitals under Ayushman Bharat

Powered by WPeMatico

Health Bulletin 30/August/2025

Here are the top health stories of the day:

Doctors, Legal Experts Oppose Lowering Age of Consent

Several doctors, psychologists, rights activists and lawyers on Thursday strongly opposed any move to reduce the age of consent from 18 to 16 years, warning that it could adversely impact the social, psychological and physical well-being of adolescents.

NHRC member Priyank Kanoongo, terming the move a ”time bomb”, which, if ”not defused”, will ”explode inside families”.

For more details, check out the full story on the link below:

Doctors, Rights Experts raise alarm over proposal to lower age of consent

Delhi HC Issues Notice to NBE, Centre Over DNB Revaluation Clause Challenge

The Delhi High Court has sought a response from the National Board of Examination (NBE) and the Centre on a plea filed by a DNB trainee doctor from Gangaram Hospital challenging the evaluation rules in the Diplomate National Board exam.

The petitioner argued that the current clause allows revaluation only if an answer is wrongly marked “not attempted,” leaving no scope to challenge ‘arbitrary’ evaluation. She claimed her answer sheets showed discrepancies, and denial of revaluation had unjustly barred her from the practical exam, jeopardizing her career.

For more details, check out the full story on the link below:

Doctor challenges ‘arbitrary’ revaluation clause in DNB exam- Delhi HC issues notice to NBE, Centre

100 Additional Delhi Hospitals to Be Added Under Ayushman Bharat Soon

Delhi Health Minister Dr Pankaj Singh on Thursday announced that the government will add 100 more hospitals under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) in the next 10 days. This move will increase the total number of empanelled hospitals in the capital to 165.

The updated list is expected to include prominent private hospitals such as Fortis Healthcare. A formal launch of the expanded network is scheduled for the first week of September.

According to the National Health Authority (NHA), which oversees the implementation of AB-PMJAY across India, 151 hospitals in Delhi are currently empanelled under the scheme—107 private and 44 government-run.

For more details, check out the full story on the link below:

Delhi Govt to empanel 100 additional hospitals under Ayushman Bharat

CDSCO Flags 46 Drug Batches for Failing Quality Tests in July

The Central Drugs Standard Control Organization (CDSCO) has declared 46 batches of medicines as “Not of Standard Quality” (NSQ) after drug samples tested by its regional and central laboratories in July 2025 failed to meet required pharmacopeial standards.

The flagged medicines include widely prescribed formulations such as antibiotics, cardiac drugs, gastrointestinal medicines, hormonal injections, and pain relief products.

These include Azithromycin Tablets IP (Aziventis-500) manufactured by Gnosis Pharmaceuticals, Heparin Injection IP 1000 IU/ml (Flagorin) manufactured by Divine Laboratories, Amikacin Sulphate Injection manufactured by SAI Parenterals, Amoxycillin and Potassium Clavulanate Tablets I.P. 625 mg manufactured by Hindustan Antibiotics, Dexamethasone Tablets IP 4mg (Dexatore-4) manufactured by United Bioceuticals, and others.

For more details, check out the full story on the link below:

46 Drug Batches Fail CDSCO Quality Test In July, Details

Powered by WPeMatico

Biogen, Eisai get USFDA nod for Leqembi Iqlik Subcutaneous Injection for maintenance dosing for early Alzheimer’s Disease

Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI IQLIK, pronounced “I Click”) for maintenance dosing.

LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Eisai, containing 360 mg/1.8 mL (200 mg/mL) that can be administered in approximately 15 seconds. LEQEMBI IQLIK auto injector is indicated for maintenance dosing to treat Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) in the U.S. After 18 months of LEQEMBI (lecanemab-irmb) intravenous (IV) treatment at 10 mg/kg every two weeks, patients may either continue IV infusions at 10 mg/kg once every four weeks or start the new weekly 360 mg subcutaneous injection using the LEQEMBI IQLIK autoinjector.

The BLA is based on LEQEMBI subcutaneous (SC) sub-studies of the Phase 3 Clarity AD open-label extension (OLE) trial in individuals with early AD, which evaluated a range of subcutaneous doses. Data shows that transitioning to the weekly LEQEMBI IQLIK autoinjector after 18 months of the initiation dose (10 mg/kg IV every two weeks) maintains clinical and biomarker benefits comparable to continued IV dosing. The safety of LEQEMBI IQLIK autoinjector was studied in over 600 patients at a range of doses as part of the Clarity AD OLE.

49 patients received a weekly 360 mg subcutaneous maintenance dose after at least 18 months of 10 mg/kg IV every two weeks.

ARIA rates in patients who received a weekly 360 mg subcutaneous maintenance dose were similar to ARIA rates reported in patients who continued with the IV dose after 18 months and are similar to the background rates of ARIA in patients without treatment. ARIA is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Most ARIA with LEQEMBI occurs within the first 6 months of IV initiation treatment.

AD is a progressive, relentless disease with amyloid beta (Aβ) and tau as hallmarks, caused by a continuous underlying neurotoxic process that begins before amyloid plaque removal and continues afterward. Only LEQEMBI fights AD in two ways – targeting both amyloid plaque and protofibrils, which can impact tau downstream. Due to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped, maintenance treatment with once-weekly SC injection or once every four weeks of IV therapy offers patients options to continue slowing the disease progression and prolong the benefit of therapy, with the goal of helping patients maintain who they are for longer.

  • In the Clarity AD core study, the mean change from baseline between the lecanemab IV once every 2 weeks treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale.
  • To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person’s ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.6, 7
  • At 48 months of treatment through the Clarity AD core study and its OLE, data showed lecanemab demonstrated a reduction in cognitive decline measured by CDR-SB of -1.75 points compared to the expected decline observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)*2 cohort.
  • Similarly, when benchmarked against the expected decline in the BioFINDER*3 cohort, lecanemab showed a reduction of -2.17 points measured by CDR-SB at the four-year mark.

Powered by WPeMatico

Chennai Doctor suffers seizure while driving, kills couple

Chennai: In a tragic incident, a government doctor suffered a seizure while driving, causing him to crash into a two-wheeler near Avadi on Thursday morning, which resulted in the death of a couple on the spot.

The accident occurred around 10:10 am on the Avadi–Poonamallee Road, when the doctor, allegedly losing consciousness while driving, crashed into the couple’s bike from behind, struck the centre median, and overturned. The couple died on the spot. 

The deceased couple, both employed in different private firms, were on their way to work when the unfortunate accident occurred. They are survived by their twin sons.

According to police reports, the doctor behind the wheel of the car, a physician at a primary health centre in Soranchery, claimed that he suffered a seizure while driving, which caused him to lose consciousness and veer into the couple’s path.

Also Read: Doctor Dies on Spot after High-Speed Crash on Ludhiana-Foerozapur Road

Speaking to TNIE, a police source said, “Around 10.10 am, as the duo were near Vasantham Nagar in Avadi, a car driven by Dr Parry Marx hit their two-wheeler from behind. It then hit the centre median and fell sideways. Due to the impact, Ariuvarasan hit a load van nearby, and Saranya was crushed beneath the car.”

The police reported that the bodies were recovered and sent to a nearby hospital, where they were declared dead. The doctor was admitted to a government hospital in Avadi and later referred to the Government Kilpauk Medical College Hospital for further treatment. According to the police, the doctor is now stable.

Also Read: Doctor arrested after car runs over 73-year-old woman

“During inquiries, Parry’s wife told us that he had suffered from seizures since his teens. We are probing to find out how he was allowed to drive despite his condition,” the source said, according to TNIE.

A case under sections 281, 106(i), and 125(b) of the BNS (Indian Penal Code) has been registered against the doctor. The investigation is still ongoing.

Powered by WPeMatico

Medical Bulletin 30/August/2025

Here are the top medical news for the day:

WHO-Endorsed Mosquito Repellent Cuts Malaria Risk by Over 50%: Study

A recent international study published in eBioMedicine has found that WHO-endorsed spatial repellent sheets can reduce mosquito bites by over 50%, offering a powerful new tool in the fight against mosquito-borne diseases such as malaria and dengue. The study analyzed data on 1.7 million mosquitoes collected over 25 years to evaluate the effectiveness of these repellents.

These spatial repellents, also called spatial emanators, are lightweight, paper-like sheets that release pyrethroid-based vapours to deter mosquitoes without requiring direct skin application, heat, or electricity. Roughly the size of a sheet of paper, they protect up to a year against mosquitoes that carry diseases including malaria, dengue, Zika, yellow fever, and West Nile virus.

The study’s findings showed that spatial repellents reduced mosquito bites by more than half on average, with some trials achieving up to 75% effectiveness against Anopheles arabiensis, a dangerous malaria vector. Importantly, the repellents worked both indoors and outdoors, offering more versatile protection compared to bed nets or insecticide sprays, which are often limited by location or time.

Malaria claims an estimated 608,000 lives annually worldwide, and current tools like insecticide-treated bed nets offer protection mainly indoors at night. Repellent creams and coils provide only limited or costly solutions. The long-lasting and easy-to-use spatial repellents thus represent a major breakthrough, especially for remote areas with poor electricity supply.

The vapours released are similar to those used in WHO-approved bed nets, with no new health risks detected in long-term use. “These are lightweight, affordable, and ideal for rural and urban settings,” the study authors said.

Reference: Chen, Ingrid Chena, Sarah L. Millera , Daniel Msellemuc , Aidi G. Lugengec , Johnson Kyeba Swaic , Nicole Acheed , Marta Andrésc,e,f , Christopher S. Bibbsg , Theeraphap Chareonviriyaphaph , J. Derek Charlwoodi , Greg Devine; Volatile pyrethroid spatial repellents for preventing mosquito bites: a systematic review and meta-analysis; eBioMedicine, Volume 0, Issue 0, 105891; DOI: 10.1016/j.ebiom.2025.105891

New Research Reveals Diabetes May Accelerate Breast Cancer Growth

A recent study published in Communications Biology by researchers at Boston University Chobanian & Avedisian School of Medicine has revealed how type 2 diabetes alters immune responses within breast tumors, helping explain why diabetic women face more aggressive breast cancer and poorer outcomes. The study focused on microscopic particles called exosomes, which circulate in the bloodstream and influence the body’s immune system.

The researchers analyzed patient-derived breast cancer organoids—miniature tumors grown in the lab—and exposed them to blood from individuals with and without type 2 diabetes. They found that exosomes from diabetic patients weakened immune cells within tumors, reducing the body’s ability to fight cancer. In contrast, organoids exposed to non-diabetic blood maintained stronger immune defenses.

Type 2 diabetes affects more than 500 million people worldwide and is linked to a 20-30% higher risk of developing breast cancer. Women with diabetes also experience greater mortality from breast cancer compared to those without diabetes. Until now, the biological reasons behind these disparities were unclear.

Lead researchers explained that diabetes-altered exosomes reprogram immune cells inside tumors, allowing cancer cells to grow more aggressively and making treatments like immunotherapy less effective. This mechanism could also apply to other cancers that evade immune responses.

The findings suggest future possibilities such as developing drugs to block harmful exosomes, customizing immunotherapy for diabetic patients, and increasing cancer screening for women with diabetes. Meanwhile, doctors emphasize prevention through blood sugar control, healthy diet, regular exercise, and maintaining a healthy weight.

This study highlighted the complex interplay between chronic diseases, reminding us that diabetes’ impacts extend beyond sugar metabolism to shape the immune system’s fight against cancer—pointing toward more personalized treatment approaches.

Reference: Ennis, C.S., Seen, M., Chen, A. et al. Plasma exosomes from individuals with type 2 diabetes drive breast cancer aggression in patient-derived organoids. Commun Biol 8, 1276 (2025). https://doi.org/10.1038/s42003-025-08663-y

Study Links Ultra-Processed Foods to Metabolic and Reproductive Harm

A recent international study published in Cell Metabolism has revealed that ultra-processed foods can cause weight gain and disrupt reproductive health, even when calorie intake is matched with minimally processed diets. The research, led by Jessica Preston at the University of Copenhagen’s NNF Center for Basic Metabolic Research, investigated the impact of food processing on metabolism and sperm quality in healthy young men.

Researchers studied 43 men aged 20 to 35, who spent three weeks on both ultra-processed and minimally processed diets, separated by a three-month washout period. Half of the participants consumed normal calorie amounts, while the other half received an additional 500 calories per day. Both diets were carefully matched for calories, protein, carbohydrates, and fats.

The findings showed that men gained around 1 kg more fat mass on the ultra-processed diet regardless of calorie intake. Additionally, several cardiovascular health markers worsened on the ultra-processed diet. Worryingly, the study also found increased levels of phthalate cxMINP, a hormone-disrupting chemical used in plastics, in men consuming ultra-processed foods. This was linked to decreases in testosterone and follicle-stimulating hormone, essential for sperm production.

“We were shocked by the extent to which ultra-processed foods disrupted body functions, even in healthy young men,” said Professor Romain Barrès, senior author of the study. He emphasized the need to reevaluate nutritional guidelines to protect against chronic diseases exacerbated by ultra-processed diets.

This study highlighted that the harm caused by ultra-processed foods goes beyond excess calorie consumption, pointing to the processed nature of these foods as a fundamental risk to metabolic and reproductive health.

Reference: Preston, J. M., et al. (2025). Effect of ultra-processed food consumption on male reproductive and metabolic health. Cell Metabolism. doi.org/10.1016/j.cmet.2025.08.004

Powered by WPeMatico

NEET MDS 2025 counselling: UP DGME releases seat matrix, merit list for stary vacancy round

Uttar Pradesh- The Department of Medical Education Training (UPDGME) has released the seat matrix for National Eligibility and Entrance Test-Master of Dental Surgery (NEET MDS) stray Vacancy Counselling round for the academic year 2025.

The seat matrix has been released in a PDF format on the official website of UPDGME. 

As per the seat matrix, a total of 178 seats are vacant across 21 Dental Colleges of Uttar Pradesh. Of these, the DJ College of Dental Sciences & Research, Ghaziabad, has the highest vacant seats and the Faculty of Dental Sciences, Lucknow, has the lowest MDS vacant seats. Below is the detailed vacant seats-

Also Read: UP DGME Releases NEET MDS Stray Vacancy Revised Schedule 2025

SEAT MATRIX

S.NO

COLLEGE NAME

VACANT SEATS

1

FACULTY OF DENTAL SCIENCES, KGMU, LUCKNOW.

1

2

SARDAR PATEL POST GRADUATE INSTITUTE OF DENTAL & MEDICAL SCIENCES, LUCKNOW.

12

3

INSTITUTE OF DENTAL STUDIES & TECHNOLOGIES, MODINAGAR, GHAZIABAD.

8

4

SCHOOL OF DENTAL SCIENCES, SHARDA UNIVERSITY, GREATER NOIDA.

5

5

CHANDRA DENTAL COLLEGE & HOSPITAL, BARABANKI.

2

6

SARASWATI DENTAL COLLEGE & HOSPITAL, LUCKNOW

7

7

CAREER POST GRADUATE INSTITUTE OF DENTAL SCIENCES & HOSPITAL, LUCKNOW.

8

8

DENTAL COLLEGE, AZAMGARH.

10

9

INDERPRASTHA DENTAL COLLEGE & HOSPITAL, GHAZIABAD.

9

10

SHREE BANKEY BIHARI DENTAL COLLEGE & RESEARCH CENTER, GHAZIABAD.

13

11

BBD COLLEGE OF DENTAL SCIENCES, LUCKNOW.

6

12

KALKA DENTAL COLLEGE, MEERUT.

17

13

INSTITUTE OF DENTAL SCIENCES, BAREILLY.

9

14

K.D. DENTAL COLLEGE & HOSPITAL, MATHURA.

6

15

KOTHIWAL DENTAL COLLEGE & RESEARCH CENTER, MORADABAD.

4

16

RAMA DENTAL COLLEGE HOSPITAL & RESEARCH CENTER, KANPUR.

11

17

SUBHARTI DENTAL COLLEGE & HOSPITAL, MEERUT.

2

18

ITS DENTAL COLLEGE, HOSPITAL & RESEARCH CENTER, GREATER NOIDA.

4

19

TEERTHANKAR MAHAVEER DENTAL COLLEGE & RESEARCH CENTER, MORDABAD.

8

20

ITS CENTER FOR DENTAL STUDIES & RESEARCH, GHAZIABAD.

8

21

DJ COLLEGE OF DENTAL SCIENCES & RESEARCH, MODINAGAR, GHAZIABAD.

28

TOTAL

178

To view the seat matrix, click the link below

https://medicaldialogues.in/pdf_upload/updgme-299323.pdf

Along with this, UPDGME has also released the NEET MDS Stray Vacancy Round Counselling UP state merit list. The merit list has been released in a PDF format on the official website of UPDGME. he merit list contains important details such as roll no, name, father’s name, UP category, UP Sub Category, Neet Marks and Neet Rank.

A total of 312 candidates’ names were mentioned in the merit list of the UP State NEET-PG (MDS) Stray Vacancy Round 2025. The list is the registered candidate data of UP NEET PG (MDS) 2025 counselling. Only those candidates who have deposited their Registration Fee and Security Money are eligible for choice filling.

To view the merit list, click the link below

https://medicaldialogues.in/pdf_upload/merit-list-299324.pdf 

Powered by WPeMatico

Zydus Wellness acquires UK based Comfort Click, forays into UK, EU markets

Ahmedabad: Zydus Wellness Limited has announced that Alidac UK Limited, a wholly owned subsidiary, has signed a definitive agreement
acquiring UK-based Comfort Click Limited including its three subsidiaries located in Ireland, US and India.

The acquisition marks Zydus Wellness’ first overseas acquisition and its entry
into the Vitamins, Minerals and Supplements (VMS) segment.
The target company, operating in UK and major
markets of Europe, posted revenues of GBP 134 million (unaudited) for the financial year ended on 30 Jun 2025
with a five-year CAGR of 57% and recorded adjusted operating profit of GBP 21 million. The VMS market in
Europe is estimated to be around GBP 11 bn. The equity value is GBP 239 million, subject to customary and
agreed adjustments under the terms of the SPA.
The company has operations across United Kingdom (UK) and Europe (EU) and is expanding
its operations in the United States of America (USA). The company has a diversified portfolio across
adult, kids and pet segments.
Comfort Click’s business portfolio comprises three brands: (i) WeightWorld which includes plant-based supplements, vitamins and minerals, collagen, omegas, probiotics, and
micronutrients, and sports nutrition for adults, (ii) maxmedix a specialty VMS gummy brand which caters to
all paediatric nutritional requirements and (iii) Animigo a natural pet VMS brand which offers a range of pet
care products.
Speaking on the development, Dr. Sharvil Patel, Chairman, Zydus Wellness Limited, “The global acquisition
of Comfort Click, a leading player in the digital vitamins, minerals and supplements space, marks a significant
step in our journey to empower consumers to make informed choices and embrace wellness-focused products
as part of their path to better health. This strategic move reflects our aspiration to be a forward-looking company
that not only anticipates consumer needs but also enables easy access to them. With Comfort Click, we are
strengthening our global capabilities, deepening our presence in digital health and personalised wellness, and
exploring scalable and sustainable models that will shape the future of wellbeing. We are excited and exploring
at new possibilities driven by innovation and a customer first approach.”
.Tarun Arora, CEO and Whole-Time Director, Zydus Wellness Limited, said, “The acquisition of
Comfort Click is a significant step forward in our journey to strengthen our leadership in the wellness space. It
aligns with our strategic vision of expanding Zydus Wellness’ international footprint while deepening our
capabilities in consumer-centric health and wellbeing solutions. Comfort Click brings a strong portfolio, a
digital-first approach, and a shared commitment to innovation and quality. We are excited to welcome the
employees, consumers, partners, and stakeholders as we work together to unlock new opportunities and advance
the wellness quotient worldwide.”

Powered by WPeMatico

New hope for healthcare: Nita Ambani announces 2000-bed Medical City in Mumbai

Mumbai: In a major step to transform the country’s healthcare landscape, Nita Ambani, Founder and Chairperson of Reliance Foundation, announced the establishment of a massive state-of-the-art 2,000-bed medical city in Mumbai.  

The facility will not just be another hospital, but a hub of healthcare innovation where advanced medical technology and artificial intelligence will work alongside some of the world’s finest doctors to provide world-class treatment at affordable costs. This initiative is set to revolutionise the health and medical industry, restructuring and reshaping it with the power of advanced technology to serve humankind better.

Also read- Haryana doctors launch hunger strike against Geo-fencing Attendance System

Sharing the announcement at the 48th Annual General Meeting of Reliance Industries, Mrs. Ambani said, “This will not be just another hospital but India’s new beacon of healthcare innovation, where AI-powered diagnostics, cutting-edge medical technology, and leading doctors from across the globe will come together to deliver care that matches the best standards in the world.”


Beyond patient care, the upcoming medical city will also house a transformative medical college, envisioned to train the next generation of doctors who will serve both India and the world. Nita Ambani emphasised that the mission is not just to expand capacity, but to make world-class healthcare accessible and affordable to every Indian.

The new project builds upon the success of the Sir H. N. Reliance Foundation Hospital, Mumbai’s top multi-speciality hospital, which recently completed a decade of service, serving millions of patients. 

Marking the milestone, Mrs. Ambani also launched “Jeevan” – a state-of-the-art extension of the hospital and the name for the upcoming medical city. The Jeevan wing will focus on pediatric cancer care through chemotherapy and immunotherapy, designed to provide children with advanced treatment in an environment filled with compassion and warmth.

“This wing will be designed to heal our little ones with world-class care and a mother’s warmth,” she explained.

Also read- AIIMS Announces 12-hour a day duty roster: Is it feasible? Here’s what doctors say

Powered by WPeMatico

Sex-selective abortion bans harm maternal and infant health, according to study

Sex-selective abortion bans (SSABs)—which prohibit the seeking of abortions based on the fetus’ sex—increase the likelihood of low birth weight and preterm births among infants born to Asian immigrant mothers, according to a new study by Yale sociologist Emma Zang.

Powered by WPeMatico